Rabbit Recombinant Monoclonal CCL1 antibody. Carrier free. Suitable for IP, WB and reacts with Human samples.
Constituents: 100% PBS
ICC/IF | IP | WB | IHC-P | Flow Cyt (Intra) | |
---|---|---|---|---|---|
Human | Not recommended | Tested | Tested | Not recommended | Not recommended |
Mouse | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Rat | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Cytokine that is chemotactic for monocytes but not for neutrophils. Binds to CCR8.
SCYA1, CCL1, C-C motif chemokine 1, Small-inducible cytokine A1, T lymphocyte-secreted protein I-309
Rabbit Recombinant Monoclonal CCL1 antibody. Carrier free. Suitable for IP, WB and reacts with Human samples.
Constituents: 100% PBS
Anti-CCL1 antibody [EPR21168-154] ab280356 is the carrier-free version of ab280371.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
The CCL1 protein also known as I-309 protein is a cytokine that plays a significant role in the immune system. Its molecular mass is approximately 10 kDa. CCL1 is secreted by activated T cells and is found extensively in the thymus. It binds to the CCR8 receptor which suggests its involvement in immune signaling. This protein belongs to the CC chemokine family which is characterized by the presence of two adjacent cysteines near the amino terminus.
CCL1 influences immune cell trafficking and activation. It attracts monocytes T lymphocytes and some types of dendritic cells to sites of inflammation. Although it is not part of a large protein complex CCL1 works with other chemokines to modulate the immune response contributing to both innate and adaptive immune mechanisms. Its expression may increase or decrease depending on the immune needs of the body.
Studies show that CCL1 participates in the chemokine signaling pathway and the effector T-cell pathway. Within the chemokine signaling pathway CCL1 interacts with other chemokines like CCL17 and proteins involved in T-cell migration. This pathway helps coordinate the movement of immune cells to sites of inflammation or injury ensuring an effective immune response.
Research links CCL1 to conditions such as asthma and rheumatoid arthritis. In asthma CCL1 levels influence the recruitment of immune cells to the lungs contributing to inflammation and airway hyper-responsiveness. Similarly in rheumatoid arthritis its interaction with CCR8 has been associated with synovial inflammation. These diseases indicate that CCL1’s role in immune cell migration can have pathological consequences when dysregulated.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using Anti-CCL1 antibody [EPR21168-154] ab280356, the same antibody clone in a different buffer formulation.
Blocking and diluting buffer and concentration: 5% NFDM/TBST
CCL1 expression is induced by PMA and anti-CD28 antibody (PMID: 22413885).
Exposure time: 37 seconds
All lanes: Western blot - Anti-CCL1 antibody [EPR21168-154] (Anti-CCL1 antibody [EPR21168-154] ab280356) at 1/1000 dilution
Lane 1: Untreated Jurkat (human t cell leukemia t lymphocyte) whole cell lysate at 40 µg
Lane 2: Jurkat treated with /ml PMA and 1ug/ml anti-CD28 antibody and 300ng/ml BFA for 21 hours, whole cell lysate at 40 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Predicted band size: 10 kDa
Observed band size: 14 kDa
This data was developed using Anti-CCL1 antibody [EPR21168-154] ab280356, the same antibody clone in a different buffer formulation.
CCL1 was immunoprecipitated from 0.35 mg Jurkat (human t cell leukemia t lymphocyte) treated with 10ng/ml PMA and 1μg/ml anti-CD28 antibody and 300ng/ml BFA for 21 hours, whole cell lysate 10 μg with Anti-CCL1 antibody [EPR21168-154] ab280356 at 1/30 dilution (2μg in 0.35mg lysates). Western blot was performed on the immunoprecipitate using Anti-CCL1 antibody [EPR21168-154] ab280356 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP)(VeriBlot for IP Detection Reagent (HRP) ab131366) was used at 1/5000 dilution.
Lane 1: Jurkat treated with 10ng/ml PMA and 1μg/ml anti-CD28 antibody and 300ng/ml BFA for 21 hours, whole cell lysate 10 μg
Lane 2: Anti-CCL1 antibody [EPR21168-154] ab280356 IP in Jurkat treated with 10ng/ml PMA and 1μg/ml anti-CD28 antibody and 300ng/ml BFA for 21 hours whole cell lysate
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of Anti-CCL1 antibody [EPR21168-154] ab280356 in Jurkat treated with 10ng/ml PMA and 1μg/ml anti-CD28 antibody and 300ng/ml BFA for 21 hours whole cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 76 seconds
This blot was developed using a higher sensitivity ECL substrate.
All lanes: Immunoprecipitation - Anti-CCL1 antibody [EPR21168-154] (Anti-CCL1 antibody [EPR21168-154] ab280356)
Predicted band size: 10 kDa
Observed band size: 14 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com